Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
SLN$19.79+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated statements of cash flows
(in thousands)
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities | ||
| Net loss after tax | $(88,612) | $(45,309) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
| Depreciation expense | 312 | 336 |
| Amortization expense | 243 | 257 |
| Share-based compensation expense | 8,074 | 16,307 |
| Net foreign exchange impacts | 11,022 | (2,581) |
| Other income, net | (3,480) | (4,472) |
| Income tax expense | 11 | 845 |
| Change in operating assets and liabilities: | ||
| Decrease/(increase) in trade receivables | 1,024 | (904) |
| Decrease/(increase) in other current assets | 6,016 | (1,330) |
| Decrease/(increase) in R&D benefit receivable | 4,041 | (2,337) |
| Decrease in other long-term assets | 3,658 | - |
| (Decrease)/increase in trade and other payables | (4,078) | 499 |
| Decrease in contract liabilities | (334) | (28,786) |
| Decrease in operating lease liabilities | (168) | (165) |
| Net cash used in operating activities | (62,271) | (67,640) |
| Cash flow from investing activities | ||
| Redemption of term deposits | 118,476 | 117,412 |
| Purchase of term deposits | (166,413) | (139,167) |
| Purchase of property, plant and equipment | (55) | (211) |
| Net cash used in investing activities | (47,992) | (21,966) |
| Cash flow from financing activities | ||
| Proceeds from issue of ordinary shares | 15 | 142,087 |
| Net cash provided by financing activities | 15 | 142,087 |
| (Decrease)/increase in cash and cash equivalents | (110,248) | 52,481 |
| Cash and cash equivalents at start of period | 121,330 | 68,789 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | 195 | 60 |
| Cash and cash equivalents at end of period | $11,277 | $121,330 |
| Supplemental disclosures of cash flow information: | ||
| Income Tax Paid net of refunds | (637) | (433) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.